Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction
The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.
Primary source
ClinicalTrials.gov registry record, November 16, 2026
A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction
Read the source: A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation